Skip to main content
. Author manuscript; available in PMC: 2022 Jan 13.
Published in final edited form as: Nano Lett. 2021 Jan 4;21(1):875–886. doi: 10.1021/acs.nanolett.0c04833

Figure 1.

Figure 1.

Schematic illustration of SNAbs and their hypothetical mechanism of action. (a) SNAbs are Janus nanoparticles bearing two distinct chemically modified faces. One of the two faces presents targeting ligands to perform the function of Fab domains in mAbs, and the other displays Fc-mimicking ligands to crosslink Fc receptors on the effector cells as Fc fragments in mAbs. (b) Once administered into patients or animals with diseases, the SNAbs circulate and recognize target cells in blood or organs of interest by binding onto their surface proteins and engaging with effector cells (e.g. macrophages, NK cells) to induce antibody-like cellular cytotoxicity or phagocytosis.